Drug intelligence / Profile preview

Ozotel-AMH

Development stage
Unknown
Lead developer
Ozone Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Ozotel-AMH is a fixed-dose combination antihypertensive medication manufactured by Ozone Pharmaceuticals. It contains three active ingredients: telmisartan (40mg), amlodipine (5mg), and hydrochlorothiazide (12.5mg). Telmisartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral vasodilation. Hydrochlorothiazide is a thiazide diuretic that acts on the distal convoluted tubule to inhibit sodium and chloride resorption, thereby increasing water excretion and reducing plasma volume. This triple therapy is typically prescribed for patients whose blood pressure is not adequately controlled by dual therapy, helping to mitigate the risk of cardiovascular complications such as stroke and myocardial infarction.

Brand names
Ozotel-AMH
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on Ozotel-AMH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ozotel-AMH.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call